Vigil Neuro
Elizabeth Thompson has extensive experience in the biometrics, clinical data management, and oncology fields. Elizabeth has held various director and manager positions at companies such as Vigil Neuroscience, Jounce Therapeutics, Sarepta Therapeutics, Ziopharm Oncology, and Eastern Cooperative Oncology Group. Elizabeth has a Master of Public Health in Epidemiology from Boston University School of Public Health and a Bachelor of Arts in English from Boston University.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.